 |
| |
| Jun-28-19 | Downgrade |
Piper Jaffray |
Overweight → Neutral |
$280 → $250 |
|
| Jun-05-19 | Upgrade |
Standpoint Research |
Hold → Buy |
|
|
| May-23-19 | Resumed |
Citigroup |
Neutral |
|
|
| May-23-19 | Initiated |
Wedbush |
Neutral |
|
|
| May-21-19 | Initiated |
Credit Suisse |
Underperform |
$198 |
|
| Apr-10-19 | Resumed |
Raymond James |
Mkt Perform |
|
|
| Mar-25-19 | Reiterated |
H.C. Wainwright |
Buy |
$363 → $300 |
|
| Mar-22-19 | Reiterated |
BMO Capital Markets |
Market Perform |
$322 → $250 |
|
| Mar-22-19 | Downgrade |
UBS |
Buy → Neutral |
$395 → $242 |
|
| Mar-22-19 | Downgrade |
Morgan Stanley |
Overweight → Underweight |
$401 → $210 |
|
| Mar-22-19 | Downgrade |
Canaccord Genuity |
Buy → Hold |
$396 → $275 |
|
| Mar-21-19 | Reiterated |
Guggenheim |
Neutral |
$325 |
|
| Mar-21-19 | Downgrade |
William Blair |
Outperform → Mkt Perform |
|
|
| Mar-21-19 | Downgrade |
Wells Fargo |
Outperform → Market Perform |
|
|
| Mar-21-19 | Downgrade |
Mizuho |
Buy → Neutral |
|
|
| Mar-21-19 | Downgrade |
JP Morgan |
Overweight → Neutral |
|
|
| Mar-21-19 | Downgrade |
Goldman |
Buy → Neutral |
|
|
| Mar-21-19 | Downgrade |
Citigroup |
Buy → Neutral |
|
|
| Mar-21-19 | Downgrade |
BofA/Merrill |
Buy → Neutral |
|
|
| Mar-21-19 | Downgrade |
Atlantic Equities |
Overweight → Neutral |
|
|
|
|
| Sep-19-19 11:30AM | Biogen's New Study to Test Higher Dose of SMA Drug Spinraza Zacks |
| 07:17AM | Alexion (ALXN) Down on News of CFO Clancy's Departure in 2019 Zacks |
| Sep-18-19 10:33AM | Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More Zacks |
| 10:04AM | Roche's Gazyva Now a Breakthrough Therapy for Lupus Nephritis Zacks |
| 07:30AM | Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients GlobeNewswire |
| Sep-17-19 04:05PM | 6 Undervalued Companies Growing Earnings GuruFocus.com |
| 07:30AM | Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index GlobeNewswire |
| Sep-16-19 11:49AM | This Biotech Stock Just Rocketed 83% On A $2 Billion Takeover Deal Investor's Business Daily |
| 11:30AM | S&P 500 buybacks decline significantly in Q2 2019; expenditures still remain higher than the pre-2018 levels PR Newswire |
| 10:17AM | The Zacks Analyst Blog Highlights: Biogen, Crocs, Casey's General Stores and Clean Harbors Zacks |
| 10:16AM | Biogen Stops Late-Stage Studies on Alzheimer's Candidate Zacks |
| Sep-14-19 06:31AM | 3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector InvestorPlace |
| Sep-13-19 04:18PM | Biogen Scraps 2 More Studies In Alzheimer's Disease And Shares Pop Investor's Business Daily |
| 11:00AM | Biogen Scraps 2 More Studies In Alzheimer's Disease And Shares Pop Investor's Business Daily |
| 10:05AM | Biogen, Eisai halt work on second of 3 clinical-stage Alzheimer's drugs American City Business Journals |
| 08:44AM | UPDATE 2-Biogen scraps two late-stage trials for Alzheimer's treatment Reuters |
| 08:42AM | What September Doldrums? Here's Why Stocks Are Moving Higher Zacks |
| 08:18AM | Biogen's stock falls after co. and Eisai to discontinue late-stage trial of Alzheimer's treatment MarketWatch |
| 08:13AM | Biogen scraps two late-stage Alzheimer's trials Reuters |
| 08:00AM | Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease PR Newswire |
| 07:45AM | Top 5 ROE Stocks to Profit as Sino-US Trade Tensions Abate Zacks |
| 05:32AM | Biogen Rises After Canceling Two Late-Stage Alzheimer's Trials TheStreet.com |
| Sep-12-19 03:15PM | Does Biogen Inc.'s (NASDAQ:BIIB) CEO Pay Matter? Simply Wall St. |
| 05:00AM | New Research Demonstrate Biogens Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum GlobeNewswire |
| Sep-11-19 07:09AM | The Daily Biotech Pulse: Lexicon Snaps Sanofi Diabetes Partnership With $260M Settlement, Celyad Offering, Multiple Sclerosis Conference Gets Underway Benzinga |
| 05:00AM | New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years GlobeNewswire |
| Sep-09-19 10:10AM | Amgen's KRAS Inhibitor Shows Response in Larger NSCLC Group Zacks |
| Sep-08-19 05:09PM | Stocks That Fell to 3-Year Lows in the Week of Sept. 6 GuruFocus.com |
| Sep-05-19 05:01PM | 6 Stocks With Low Price-Sales Ratios GuruFocus.com |
| 08:05AM | 5 Price-to-Book Value Picks for September Zacks |
| Sep-04-19 10:17AM | Biotech vet George Scangos steers new company toward nine-figure IPO American City Business Journals |
| 09:37AM | Novartis Inks Commercialization Deal for Tysabri Biosimilar Zacks |
| Sep-01-19 07:00AM | Better Buy: Gilead Sciences vs. Biogen Motley Fool |
| Aug-30-19 08:04AM | Novartis' (NVS) MS Drug Achieves Goals in Late-Stage Studies Zacks |
| Aug-28-19 02:15PM | Ionis (IONS) Out-licenses Hepatitis B Virus Program to Glaxo Zacks |
| 08:51AM | 5 ROE Stocks to Profit as Trade War Flip-Flops Rattle Market Zacks |
| Aug-25-19 02:00PM | Better Buy: Biogen vs. Celgene Motley Fool |
| Aug-24-19 05:46PM | Stocks That Fell to 3-Year Lows in the Week of Aug. 23 GuruFocus.com |
| Aug-21-19 07:10AM | Could The Biogen Inc. (NASDAQ:BIIB) Ownership Structure Tell Us Something Useful? Simply Wall St. |
| 06:00AM | Biogen- Buybacks and Biotech MoneyShow |
| Aug-20-19 07:30AM | Biogen and Invitae Announce Availability of Rapid Results in Genetic Testing Program for Spinal Muscular Atrophy (SMA) to Improve Speed of Diagnosis for Patients GlobeNewswire |
| Aug-19-19 08:04AM | AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA Zacks |
| Aug-14-19 09:35AM | Amgen (AMGN) Soars to 52-Week High, Time to Cash Out? Zacks |
| 09:10AM | Are Investors Undervaluing Biogen (BIIB) Right Now? Zacks |
| Aug-13-19 10:43AM | Mergers & Acquisitions Take Center Stage in Biotech Industry Zacks |
| Aug-12-19 09:09AM | Top Ranked Momentum Stocks to Buy for August 12th Zacks |
| 08:59AM | 5 ROE Stocks to Profit as Trade War Spurs Volatility Zacks |
| Aug-08-19 10:17AM | PDL BioPharma (PDLI) Q2 Earnings Top Mark, Revenues Fall Y/Y Zacks |
| 09:26AM | Intercept (ICPT) Q2 Earnings & Sales Beat, NASH in Focus Zacks |
| Aug-07-19 07:54PM | Sarepta moves beyond rare disease, eyes multiple sclerosis gene therapy American City Business Journals |
| 06:45AM | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks |
| Aug-06-19 04:47PM | Edited Transcript of BIIB earnings conference call or presentation 23-Jul-19 12:00pm GMT Thomson Reuters StreetEvents |
| 04:22PM | Biotech ETFs in Focus on Impressive Q2 Earnings Results Zacks |
| Aug-02-19 12:20PM | Top Ranked Momentum Stocks to Buy for August 2nd Zacks |
| 06:04AM | 5 years later, Ice Bucket Challenge's impact on drug research still unfolding American City Business Journals |
| 05:00AM | Biogen on the brink: One of the state's largest drugmakers faces a crisis American City Business Journals |
| Aug-01-19 09:15AM | Stocks Advance in July Despite Rate Cut Selloff Zacks |
| 06:00AM | Biogen- A Biotech Buyback Bet MoneyShow |
| 01:00AM | Long-Term Outperformance Is the Norm at This Large-Cap Fund Morningstar |
| Jul-31-19 12:00PM | Top Ranked Momentum Stocks to Buy for July 31st Zacks |
| 07:11AM | Biogen (NASDAQ:BIIB) Seems To Use Debt Quite Sensibly Simply Wall St. |
| Jul-30-19 03:05PM | Biogen Hedged Its Bet and Won Big Motley Fool |
| 08:45AM | 3 Reasons Growth Investors Will Love Biogen (BIIB) Zacks |
| 08:00AM | The 5 Worst S&P 500 Stocks Are Costing You $22.3 Billion; Here's Why Investor's Business Daily |
| 07:30AM | Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis GlobeNewswire |
| Jul-29-19 10:32AM | Zacks.com featured highlights include: PepsiCo, T. Rowe Price, Biogen, Lockheed Martin and Northrop Grumman Zacks |
| Jul-26-19 01:45PM | Alkermes Bounces Back -- but Not Enough Motley Fool |
| 12:00PM | AbbVie Discontinued a Drug Trial. Biogen Stock Is Falling. Barrons.com |
| 10:38AM | Alkermes (ALKS) Earnings and Sales Beat Estimates in Q2 Zacks |
| 08:20AM | Top 5 ROE Stocks to Buy as Dovish Fed Stance Spurs Volatility Zacks |
| Jul-25-19 02:58PM | Top Analyst Reports for Texas Instruments, Blackstone & Northrop Grumman Zacks |
| Jul-24-19 03:31PM | Biogen Raises Guidance as It Looks to the Pipeline for Growth Motley Fool |
| 10:58AM | Biotech Stock Roundup: BIIB Q2 Earnings Top & CELG's Otezla Label Expanded Zacks |
| 07:15AM | Celgene, Bristol-Myers and AbbVie still to report earnings this week: Heres what to expect MarketWatch |
| Jul-23-19 04:41PM | Biogen Earnings Crush Forecasts; But Pay Attention To These Two Elements Investor's Business Daily |
| 02:43PM | Biogen tops earnings expectations, but still has some longer-term issues to address MarketWatch |
| 01:23PM | Biogen Inc (BIIB) Q2 2019 Earnings Call Transcript Motley Fool |
| 11:42AM | Biogen Earnings: BIIB Stock Surges on Big Q2 Earnings Beat InvestorPlace |
| 10:42AM | Biogen downplays premature talk of competition for SMA drug Spinraza American City Business Journals |
| 10:16AM | Biogen (BIIB) Up on Q2 Earnings & Sales Beat, Raised View Zacks |
| 09:56AM | Biogens Good Quarter Delays Drugmakers Future Reckoning Bloomberg |
| 08:56AM | Biogen (BIIB) Q2 Earnings & Sales Beat Estimates Zacks |
| 08:39AM | Biogens Earnings Beat Forecasts, but 1 Key Drug Fell Short Barrons.com |
| 08:01AM | The Fed cant stop a market meltdown, warns forecaster who called the 2008 housing bust MarketWatch |
| 07:29AM | US STOCKS-Futures rise after better-than-expected earnings Reuters |
| 07:26AM | The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation Benzinga |
| 07:11AM | Biotech group Biogen boosted by sales of key drugs Financial Times |
| 06:58AM | UPDATE 3-Multiple sclerosis drug helps Biogen beat Wall St profit expectations Reuters |
| 06:45AM | Biogen's stock jumps after big earnings beat, raised outlook MarketWatch |
| 06:39AM | Biogen profit rises 72% Reuters |
| 05:36AM | Biogen Rises on Strong Second-Quarter Earnings, Guidance Boost TheStreet.com |
| 04:34AM | Stocks - Lockheed Martin, Hasbro, Coca-Cola, Starbucks Rise Premarket Investing.com |
| 02:47AM | Biogen Earnings, Revenue Beat in Q2 Investing.com |
| Jul-22-19 04:09PM | Biogen Earnings: Here's What Investors Are Hoping To See In Report Investor's Business Daily |
| 01:58PM | MS Franchise, Spinraza Likely to Be Key Catalysts for Biogen Stock InvestorPlace |
| Jul-20-19 09:53AM | The Week Ahead In Biotech: Pharma Earnings Pick Up Pace Benzinga |
| Jul-19-19 09:35AM | Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2? Zacks |
| Jul-17-19 03:22PM | The Multibillion-Dollar Race for Gene Therapy Manufacturing Is On Motley Fool |
| Jul-16-19 02:14PM | Eisai boosts focus on Alzheimer's with new research facility, funding American City Business Journals |
| 10:31AM | Biogen (BIIB) Reports Next Week: Wall Street Expects Earnings Growth Zacks |
|
|
|
|
| Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Gregory Ginger | EVP, Human Resources | Aug 01 | Option Exercise | 0.00 | 179 | 0 | 2,295 | Aug 05 04:20 PM | | Karp Daniel | EVP, Corporate Development | Jul 02 | Option Exercise | 0.00 | 196 | 0 | 322 | Jul 05 04:51 PM | | Ehlers Michael D | EVP, Research and Development | Jun 01 | Option Exercise | 0.00 | 1,126 | 0 | 8,525 | Jun 04 04:56 PM | | Vounatsos Michel | Chief Executive Officer | May 02 | Option Exercise | 0.00 | 1,480 | 0 | 22,487 | May 06 04:20 PM | | DENNER ALEXANDER J | Director | May 02 | Buy | 231.24 | 38,000 | 8,787,120 | 643,000 | May 02 05:06 PM | | DENNER ALEXANDER J | Director | May 01 | Buy | 229.46 | 30,000 | 6,883,800 | 605,000 | May 02 05:06 PM | | Vounatsos Michel | Chief Executive Officer | May 01 | Buy | 231.48 | 4,351 | 1,007,169 | 21,007 | May 02 04:30 PM | | DENNER ALEXANDER J | Director | Apr 30 | Buy | 229.25 | 50,342 | 11,540,904 | 575,000 | May 02 05:06 PM | | PANGIA ROBERT W | Director | Mar 18 | Option Exercise | 52.22 | 6,114 | 319,273 | 24,701 | Mar 19 04:08 PM | | PANGIA ROBERT W | Director | Mar 18 | Sale | 328.55 | 6,114 | 2,008,755 | 18,587 | Mar 19 04:08 PM | | McKenzie Paul | EVP Pharmaceutical Oper & Tech | Mar 01 | Option Exercise | 0.00 | 568 | 0 | 7,488 | Mar 05 04:17 PM | | ALEXANDER SUSAN H | EVP Chief Legal Officer & Sec. | Feb 22 | Option Exercise | 38.51 | 8,058 | 310,285 | 36,085 | Feb 26 05:09 PM | | Sandrock Alfred | EVP, Chief Medical Officer | Feb 22 | Option Exercise | 0.00 | 1,663 | 0 | 11,148 | Feb 26 05:07 PM | | Vounatsos Michel | Chief Executive Officer | Feb 15 | Option Exercise | 0.00 | 5,269 | 0 | 18,914 | Feb 20 06:10 PM | | Sandrock Alfred | EVP, Chief Medical Officer | Feb 15 | Option Exercise | 0.00 | 1,318 | 0 | 10,071 | Feb 20 06:08 PM | | McKenzie Paul | EVP Pharmaceutical Oper & Tech | Feb 15 | Option Exercise | 0.00 | 1,448 | 0 | 7,968 | Feb 20 06:07 PM | | Ehlers Michael D | EVP, Research and Development | Feb 15 | Option Exercise | 0.00 | 1,685 | 0 | 8,526 | Feb 20 05:54 PM | | ALEXANDER SUSAN H | EVP Chief Legal Officer & Sec. | Feb 15 | Option Exercise | 0.00 | 1,685 | 0 | 28,776 | Feb 20 05:53 PM | | Vounatsos Michel | Chief Executive Officer | Feb 12 | Option Exercise | 0.00 | 6,899 | 0 | 16,267 | Feb 14 06:33 PM | | Sandrock Alfred | EVP, Chief Medical Officer | Feb 12 | Option Exercise | 0.00 | 4,643 | 0 | 9,452 | Feb 14 06:29 PM | | McKenzie Paul | EVP Pharmaceutical Oper & Tech | Feb 12 | Option Exercise | 0.00 | 3,062 | 0 | 7,059 | Feb 14 06:17 PM | | Gregory Ginger | EVP, Human Resources | Feb 12 | Option Exercise | 0.00 | 1,836 | 0 | 2,561 | Feb 14 06:10 PM | | Ehlers Michael D | EVP, Research and Development | Feb 12 | Option Exercise | 0.00 | 3,827 | 0 | 7,639 | Feb 14 06:07 PM | | ALEXANDER SUSAN H | EVP Chief Legal Officer & Sec. | Feb 12 | Option Exercise | 0.00 | 3,268 | 0 | 27,710 | Feb 14 06:04 PM | | DENNER ALEXANDER J | Director | Feb 01 | Buy | 328.45 | 7,000 | 2,299,163 | 524,658 | Feb 01 04:19 PM | | DENNER ALEXANDER J | Director | Jan 31 | Buy | 330.52 | 25,800 | 8,527,393 | 517,658 | Feb 01 04:19 PM | | DENNER ALEXANDER J | Director | Jan 30 | Buy | 324.86 | 30,000 | 9,745,851 | 491,858 | Feb 01 04:19 PM | | CAPELLO JEFFREY D | EVP & Chief Financial Officer | Jan 02 | Option Exercise | 0.00 | 1,331 | 0 | 1,331 | Jan 04 04:17 PM | | Guindo Chirfi | EVP Glob. Mkt Acc & Cust Innov | Dec 01 | Option Exercise | 0.00 | 602 | 0 | 2,721 | Dec 04 08:21 PM | | Ehlers Michael D | EVP, Research and Development | Sep 26 | Sale | 350.00 | 1,000 | 350,000 | 4,281 | Sep 27 04:16 PM |
|
|
|
|
|
|
